Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematololgy-Oncology Fellowship, Medicine, Duke University School of Medicine 2005 - 2008
  • Internal Medicine Residency, Medicine, Duke University School of Medicine 2002 - 2005
  • M.D., East Carolina University, Brody School of Medicine 2002
• 

  Previous Appointments & Affiliations

  • Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2019 - 2020
• 

  Leadership & Clinical Positions at Duke

  • Medical Director of the Brain and Spine Metastases Program, Duke Cancer Institute
• Research
• 

  Selected Grants

  • A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY-461) IN PARTICIPANTS WITH BRAF V600-MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT awarded by Pfizer, Inc. 2020 - 2025
  • An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Br awarded by AstraZeneca Pharmaceuticals, LP 2021 - 2025
  • A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors awarded by Suzhou Zanrong Pharma Limited 2020 - 2025
  • ABL-regulated transcriptional and epigenetic networks promote outgrowth of breast cancer metastases revealing novel therapeutic targets awarded by Department of Defense 2022 - 2024
  • ABL-regulated transcriptional and epigenetic networks promote outgrowth of breast cancer metastases revealing novel therapeutic targets awarded by Department of Defense 2022 - 2024
  • R01 Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis awarded by National Institutes of Health 2020 - 2024
  • A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician's Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD) awarded by Angiochem Inc. 2019 - 2024
  • Retrospective tissue study HER2-positive breast cancer prediction of brain metastasis awarded by Caris Life Sciences 2021 - 2023
  • T32 UNC - Duke Immunotherapy Training Program awarded by University of North Carolina - Chapel Hill 2021 - 2022
  • Discovery and validation of putative oncogenic ROS1 alterations in metastatic breast cancer awarded by Metavivor 2020 - 2022
  • Dr. Anders-Cancer Research awarded by 5 for the Fight 2021
  • Immunotherapy to treat Triple Negative Breast Cancer Brain Metastases awarded by University of North Carolina - Chapel Hill 2019 - 2021
  • In Vitro Fertilization Outcomes in Women Diagnosed with Cancer awarded by University of North Carolina - Chapel Hill 2020 - 2021
  • Molecular Dissection and Immune Characterization of Breast Cancer Brain Metastases to Predict Outcomes and Reveal Novel Therapeutic Strategies awarded by Conquer Cancer Foundation 2019
• 

  External Relationships

  • AstraZeneca
  • Athenex
  • BioMed Central
  • Curio Healthcare
  • Elucida Oncology, Inc
  • Genentech, Inc (Roche Holding)
  • George Washington University
  • Hawaii Society of Oncology
  • Immunomedics
  • Ipsen
  • Jones Bartlett Learning (publishers)
  • Novartis
  • OncLive
  • Physician Education Resource
  • Research To Practice
  • Seattle Genetics
  • UpToDate
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Sambade, Maria J., Grace Prince, Allison M. Deal, Dimitri Trembath, Megan McKee, Amy Garrett, Kevin Keith, et al. “Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.” Breast Cancer Res Treat 176, no. 2 (July 2019): 321–28. https://doi.org/10.1007/s10549-019-05211-1.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.